225 related articles for article (PubMed ID: 30739825)
1. Experience-based discovery (EBD) of aryl hydrazines as new scaffolds for the development of LSD1/KDM1A inhibitors.
Li ZR; Wang S; Yang L; Yuan XH; Suo FZ; Yu B; Liu HM
Eur J Med Chem; 2019 Mar; 166():432-444. PubMed ID: 30739825
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, structure-activity relationship studies and biological characterization of new [1,2,4]triazolo[1,5-a]pyrimidine-based LSD1/KDM1A inhibitors.
Wang S; Li ZR; Suo FZ; Yuan XH; Yu B; Liu HM
Eur J Med Chem; 2019 Apr; 167():388-401. PubMed ID: 30780087
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors.
Culhane JC; Wang D; Yen PM; Cole PA
J Am Chem Soc; 2010 Mar; 132(9):3164-76. PubMed ID: 20148560
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy.
Duan Y; Qin W; Suo F; Zhai X; Guan Y; Wang X; Zheng Y; Liu H
Bioorg Med Chem; 2018 Dec; 26(23-24):6000-6014. PubMed ID: 30448189
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of [1,2,4]triazolo[1,5-a]pyrimidines as potent lysine specific demethylase 1 (LSD1/KDM1A) inhibitors.
Wang S; Zhao LJ; Zheng YC; Shen DD; Miao EF; Qiao XP; Zhao LJ; Liu Y; Huang R; Yu B; Liu HM
Eur J Med Chem; 2017 Jan; 125():940-951. PubMed ID: 27769034
[TBL] [Abstract][Full Text] [Related]
6. [1,2,3]Triazolo[4,5-d]pyrimidine derivatives incorporating (thio)urea moiety as a novel scaffold for LSD1 inhibitors.
Li ZH; Ma JL; Liu GZ; Zhang XH; Qin TT; Ren WH; Zhao TQ; Chen XH; Zhang ZQ
Eur J Med Chem; 2020 Feb; 187():111989. PubMed ID: 31881456
[TBL] [Abstract][Full Text] [Related]
7. Identifying the novel inhibitors of lysine-specific demethylase 1 (LSD1) combining pharmacophore-based and structure-based virtual screening.
Sun XD; Zheng YC; Ma CY; Yang J; Gao QB; Yan Y; Wang ZZ; Li W; Zhao W; Liu HM; Ding L
J Biomol Struct Dyn; 2019 Oct; 37(16):4200-4214. PubMed ID: 30366512
[TBL] [Abstract][Full Text] [Related]
8. Discovery of new tranylcypromine derivatives as highly potent LSD1 inhibitors.
Huang MJ; Guo JW; Fu YD; You YZ; Xu WY; Song TY; Li R; Chen ZT; Huang LH; Liu HM
Bioorg Med Chem Lett; 2021 Jun; 41():127993. PubMed ID: 33775841
[TBL] [Abstract][Full Text] [Related]
9. Identification of Novel Selective Lysine-Specific Demethylase 1 (LSD1) Inhibitors Using a Pharmacophore-Based Virtual Screening Combined with Docking.
Zhou C; Kang D; Xu Y; Zhang L; Zha X
Chem Biol Drug Des; 2015 Jun; 85(6):659-71. PubMed ID: 25346381
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological activity of 3-oxoamino-benzenesulfonamides as selective and reversible LSD1 inhibitors.
Xi J; Xu S; Wu L; Ma T; Liu R; Liu YC; Deng D; Gu Y; Zhou J; Lan F; Zha X
Bioorg Chem; 2017 Jun; 72():182-189. PubMed ID: 28460360
[TBL] [Abstract][Full Text] [Related]
11. Fluorinated tranylcypromine analogues as inhibitors of lysine-specific demethylase 1 (LSD1, KDM1A).
Borrello MT; Schinor B; Bartels K; Benelkebir H; Pereira S; Al-Jamal WT; Douglas L; Duriez PJ; Packham G; Haufe G; Ganesan A
Bioorg Med Chem Lett; 2017 May; 27(10):2099-2101. PubMed ID: 28390942
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of tetrahydroquinoline-based reversible LSD1 inhibitors.
Wang X; Zhang C; Zhang X; Yan J; Wang J; Jiang Q; Zhao L; Zhao D; Cheng M
Eur J Med Chem; 2020 May; 194():112243. PubMed ID: 32229389
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological activity of 4-(4-benzyloxy)phenoxypiperidines as selective and reversible LSD1 inhibitors.
Xi J; Xu S; Zhang L; Bi X; Ren Y; Liu YC; Gu Y; Xu Y; Lan F; Zha X
Bioorg Chem; 2018 Aug; 78():7-16. PubMed ID: 29524666
[TBL] [Abstract][Full Text] [Related]
14. Histone H3 peptide based LSD1-selective inhibitors.
Kakizawa T; Ota Y; Itoh Y; Tsumoto H; Suzuki T
Bioorg Med Chem Lett; 2015 May; 25(9):1925-8. PubMed ID: 25827526
[TBL] [Abstract][Full Text] [Related]
15. Intermolecular insights into allosteric inhibition of histone lysine-specific demethylase 1.
Zhang X; Sun Y; Zhang Z; Wang H; Wang J; Zhao D
Biochim Biophys Acta Gen Subj; 2021 Nov; 1865(11):129990. PubMed ID: 34390793
[TBL] [Abstract][Full Text] [Related]
16. Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity.
Schmitt ML; Hauser AT; Carlino L; Pippel M; Schulz-Fincke J; Metzger E; Willmann D; Yiu T; Barton M; Schüle R; Sippl W; Jung M
J Med Chem; 2013 Sep; 56(18):7334-42. PubMed ID: 24007511
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, and In Vitro Evaluation of Novel Histone H3 Peptide-Based LSD1 Inactivators Incorporating α,α-Disubstituted Amino Acids with γ-Turn-Inducing Structures.
Ota Y; Kakizawa T; Itoh Y; Suzuki T
Molecules; 2018 May; 23(5):. PubMed ID: 29734782
[TBL] [Abstract][Full Text] [Related]
18. Identification of selective and reversible LSD1 inhibitors with anti-metastasis activity by high-throughput docking.
Li L; Li R; Wang Y
Bioorg Med Chem Lett; 2019 Feb; 29(4):544-548. PubMed ID: 30611617
[TBL] [Abstract][Full Text] [Related]
19. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
Dai XJ; Liu Y; Xiong XP; Xue LP; Zheng YC; Liu HM
J Med Chem; 2020 Dec; 63(23):14197-14215. PubMed ID: 32931269
[TBL] [Abstract][Full Text] [Related]
20. Identification of SNAIL1 Peptide-Based Irreversible Lysine-Specific Demethylase 1-Selective Inactivators.
Itoh Y; Aihara K; Mellini P; Tojo T; Ota Y; Tsumoto H; Solomon VR; Zhan P; Suzuki M; Ogasawara D; Shigenaga A; Inokuma T; Nakagawa H; Miyata N; Mizukami T; Otaka A; Suzuki T
J Med Chem; 2016 Feb; 59(4):1531-44. PubMed ID: 26700437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
